[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 37 of about 37
1. Kaufmann AM, Nieland JD, Jochmus I, Baur S, Friese K, Gabelsberger J, Gieseking F, Gissmann L, Glasschröder B, Grubert T, Hillemanns P, Höpfl R, Ikenberg H, Schwarz J, Karrasch M, Knoll A, Küppers V, Lechmann M, Lelle RJ, Meissner H, Müller RT, Pawlita M, Petry KU, Pilch H, Walek E, Schneider A: Vaccination trial with HPV16 L1E7 chimeric virus-like particles in women suffering from high grade cervical intraepithelial neoplasia (CIN 2/3). Int J Cancer; 2007 Dec 15;121(12):2794-800
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Vaccination trial with HPV16 L1E7 chimeric virus-like particles in women suffering from high grade cervical intraepithelial neoplasia (CIN 2/3).
  • Persistent infection with human papillomaviruses (HPV) is a prerequisite for the development of cervical cancer.
  • Vaccination with virus-like particles (VLP) has demonstrated efficacy in prophylaxis but lacks therapeutic potential.
  • We have performed a first clinical trial to gain information about the safety and to generate preliminary data on the therapeutic potential of the CVLP in humans.
  • A randomized, double blind, placebo-controlled clinical trial has been conducted in 39 HPV16 mono-infected high grade cervical intraepithelial neoplasia (CIN) patients (CIN 2/3).
  • Antibodies with high titers against HPV16 L1 and low titers against HPV16 E7 as well as cellular immune responses against both proteins were induced.
  • A trend for histological improvement to CIN 1 or normal was seen in 39% of the patients receiving the vaccine and only 25% of the placebo recipients.
  • [MeSH-major] Cancer Vaccines / therapeutic use. Cervical Intraepithelial Neoplasia / drug therapy. Cervical Intraepithelial Neoplasia / virology. Human papillomavirus 16 / immunology. Oncogene Proteins, Fusion / therapeutic use. Oncogene Proteins, Viral / therapeutic use. Papillomavirus Vaccines / therapeutic use. Uterine Cervical Neoplasms / drug therapy. Uterine Cervical Neoplasms / virology
  • [MeSH-minor] Adult. Aged. DNA, Viral / drug effects. DNA, Viral / isolation & purification. Double-Blind Method. Drug Administration Schedule. Female. Humans. Middle Aged. Papillomavirus Infections / complications. Papillomavirus Infections / drug therapy. Papillomavirus Infections / immunology. Time Factors. Treatment Outcome. Tumor Virus Infections / complications. Tumor Virus Infections / drug therapy. Tumor Virus Infections / immunology


2. Hougardy BM, Reesink-Peters N, van den Heuvel FA, ten Hoor KA, Hollema H, de Vries EG, de Jong S, van der Zee AG: A robust ex vivo model for evaluation of induction of apoptosis by rhTRAIL in combination with proteasome inhibitor MG132 in human premalignant cervical explants. Int J Cancer; 2008 Sep 15;123(6):1457-65
International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A robust ex vivo model for evaluation of induction of apoptosis by rhTRAIL in combination with proteasome inhibitor MG132 in human premalignant cervical explants.
  • Development of medical therapies for high-grade cervical intraepithelial neoplasia (CIN II/III) is hampered by the lack of CIN II/III cell lines.
  • Proteasome inhibition by MG132 sensitized cervical cancer cell lines to recombinant human (rh)TRAIL.
  • In our study, we aimed to develop an ex vivo model for CIN II/III and to investigate the apoptosis-inducing effect of rhTRAIL and/or MG132 in cervical explants from CIN II/III patients.
  • A short-term ex vivo culture system was optimized for cervical biopsies, in which explants from normal cervix and CIN II/III lesions were exposed to either rhTRAIL (1 microg/ml), MG132 (5 microM) or the combination and compared to untreated explants for apoptosis induction.
  • Normal cervix (n = 90) and CIN II/III (n = 24) explants could be reproducibly put in culture and kept viable for up to 7 days using a transwell membrane system.
  • CIN II/III explants (n = 5) were highly sensitive to rhTRAIL plus MG132 (mean % apoptosis: 91 +/- 5) compared to normal cervix (n = 10) treated with rhTRAIL plus MG132 (mean % apoptosis: 24 +/- 10, p < 0.0001), while monotherapy with either rhTRAIL, MG132 or medium resulted in a mean % apoptosis <10 in both CIN II/III and normal cervix.
  • Our ex vivo model system allows preclinical evaluation of (topical) medical therapies for CIN II/III.
  • A strong synergistic apoptosis-inducing effect of the combination of rhTRAIL and MG132, especially in CIN II/III lesions indicates that rhTRAIL combined with proteasome inhibitors deserves exploration as medical treatment for CIN II/III.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / pharmacology. Apoptosis / drug effects. Cervical Intraepithelial Neoplasia / drug therapy. Leupeptins / pharmacology. TNF-Related Apoptosis-Inducing Ligand / pharmacology. Uterine Cervical Neoplasms / drug therapy
  • [MeSH-minor] Cell Culture Techniques / methods. Cells, Cultured. Female. Humans. Immunohistochemistry. Precancerous Conditions / drug therapy. Precancerous Conditions / pathology. Recombinant Proteins / pharmacology

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2008 Wiley-Liss, Inc.
  • (PMID = 18567003.001).
  • [ISSN] 1097-0215
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Leupeptins; 0 / Recombinant Proteins; 0 / TNF-Related Apoptosis-Inducing Ligand; 0 / TNFSF10 protein, human; 133407-82-6 / benzyloxycarbonylleucyl-leucyl-leucine aldehyde
  •  go-up   go-down


3. Balasubramani L, Orbell S, Hagger M, Brown V, Tidy J: Do women with high-grade cervical intraepithelial neoplasia prefer a see and treat option in colposcopy? BJOG; 2007 Jan;114(1):39-45
International Agency for Research on Cancer - Screening Group. diagnostics - Colposcopy and Treatment of Cervical Intraepithelial Neoplasia: A Beginner's Manual .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Do women with high-grade cervical intraepithelial neoplasia prefer a see and treat option in colposcopy?
  • OBJECTIVE: To compare women's experiences of either see and treat (ST) or defer and treat (DT) at first visit to colposcopy following abnormal cytology.
  • SAMPLE: A total of 272 women with high-grade cervical intraepithelial neoplasia (CIN) referred to colposcopy.
  • METHODS: A total of 136 women receiving ST and a matched sample of women receiving DT (N = 136) were sent a postal questionnaire 7 days after first appointment at colposcopy to assess evaluations of their experience, psychological distress and relief.
  • RESULTS: Women undergoing ST were significantly less anxious and more relieved than those undergoing DT.
  • [MeSH-major] Anxiety / etiology. Cervical Intraepithelial Neoplasia / psychology. Colposcopy / psychology. Patient Satisfaction. Uterine Cervical Neoplasms / psychology


Advertisement
4. Giraudo E, Inoue M, Hanahan D: An amino-bisphosphonate targets MMP-9-expressing macrophages and angiogenesis to impair cervical carcinogenesis. J Clin Invest; 2004 Sep;114(5):623-33
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] An amino-bisphosphonate targets MMP-9-expressing macrophages and angiogenesis to impair cervical carcinogenesis.
  • A mouse model involving the human papillomavirus type-16 oncogenes develops cervical cancers by lesional stages analogous to those in humans.
  • In this study the angiogenic phenotype was characterized, revealing intense angiogenesis in high-grade cervical intraepithelial neoplasias (CIN-3) and carcinomas.
  • ZA therapy increased neoplastic epithelial and endothelial cell apoptosis without affecting hyperproliferation, indicating that ZA was not antimitotic.
  • Given its track record in clinical use with limited toxicity, ZA holds promise as an "unconventional" MMP-9 inhibitor for antiangiogenic therapy of cervical cancer and potentially for additional cancers and other diseases where MMP-9 expression by infiltrating macrophages is evident.
  • [MeSH-major] Cervical Intraepithelial Neoplasia / blood supply. Diphosphonates / pharmacology. Imidazoles / pharmacology. Macrophages / drug effects. Matrix Metalloproteinase Inhibitors. Neovascularization, Pathologic / drug therapy. Uterine Cervical Neoplasms / blood supply
  • [MeSH-minor] Angiogenesis Inhibitors / pharmacology. Animals. Cell Movement / drug effects. Enzyme Activation / drug effects. Female. Humans. Macrophage Activation / drug effects. Matrix Metalloproteinase 9 / metabolism. Mice. Mice, Transgenic. Vascular Endothelial Growth Factors / metabolism

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Res. 2000 Mar 1;60(5):1267-75 [10728686.001]
  • [Cites] Cancer Res. 2003 Oct 1;63(19):6537-42 [14559848.001]
  • [Cites] Cancer Res. 2000 Jun 1;60(11):2949-54 [10850442.001]
  • [Cites] Cancer. 2000 Jun 15;88(12 Suppl):2961-78 [10898340.001]
  • [Cites] Nat Cell Biol. 2000 Oct;2(10):737-44 [11025665.001]
  • [Cites] Cell. 2000 Oct 27;103(3):481-90 [11081634.001]
  • [Cites] Bone. 2001 May;28(5):465-73 [11344045.001]
  • [Cites] Int J Biochem Cell Biol. 2001 Oct;33(10):960-70 [11470230.001]
  • [Cites] J Biol Chem. 2003 Oct 31;278(44):43603-14 [12933798.001]
  • [Cites] Nat Rev Cancer. 2004 Jan;4(1):71-8 [14708027.001]
  • [Cites] Cancer Res. 2004 Feb 1;64(3):952-61 [14871825.001]
  • [Cites] Development. 1992 Feb;114(2):447-56 [1317291.001]
  • [Cites] Cancer Res. 1994 Feb 1;54(3):800-4 [7508337.001]
  • [Cites] J Virol. 1994 Jul;68(7):4358-68 [7515971.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Oct 23;98(22):12485-90 [11606713.001]
  • [Cites] Science. 2002 Mar 29;295(5564):2387-92 [11923519.001]
  • [Cites] Br J Cancer. 2002 May 6;86(9):1479-86 [11986784.001]
  • [Cites] Cell. 2002 May 31;109(5):625-37 [12062105.001]
  • [Cites] Cancer Cell. 2002 May;1(4):339-53 [12086849.001]
  • [Cites] J Natl Cancer Inst. 2002 Aug 7;94(15):1134-42 [12165638.001]
  • [Cites] J Pharmacol Exp Ther. 2002 Sep;302(3):1055-61 [12183663.001]
  • [Cites] Br J Cancer. 2002 Aug 27;87(5):537-44 [12189553.001]
  • [Cites] Cancer Cell. 2002 Oct;2(4):289-300 [12398893.001]
  • [Cites] Oncologist. 2002;7(5):393-400 [12401901.001]
  • [Cites] Cancer Res. 2002 Nov 15;62(22):6538-44 [12438248.001]
  • [Cites] Clin Cancer Res. 2003 Jan;9(1):295-306 [12538482.001]
  • [Cites] Cancer. 2003 Feb 1;97(3 Suppl):840-7 [12548584.001]
  • [Cites] Anticancer Res. 2002 Nov-Dec;22(6C):3925-31 [12553014.001]
  • [Cites] Br J Cancer. 2003 Jan 13;88(1):63-73 [12556961.001]
  • [Cites] J Bone Miner Res. 2003 Feb;18(2):204-12 [12568397.001]
  • [Cites] Curr Opin Hematol. 2003 Mar;10(2):136-41 [12579040.001]
  • [Cites] Trends Mol Med. 2003 Mar;9(3):109-17 [12657432.001]
  • [Cites] J Cancer Res Clin Oncol. 2003 Feb;129(2):123-31 [12669237.001]
  • [Cites] J Biol Chem. 2003 Apr 25;278(17):15056-64 [12586837.001]
  • [Cites] Circ Res. 2003 May 2;92(8):827-39 [12730128.001]
  • [Cites] Nature. 2003 May 15;423(6937):337-42 [12748652.001]
  • [Cites] Nat Rev Cancer. 2003 Jun;3(6):401-10 [12778130.001]
  • [Cites] J Urol. 2003 Jul;170(1):246-52 [12796698.001]
  • [Cites] J Immunol. 2003 Jul 1;171(1):142-51 [12816992.001]
  • [Cites] Cancer Cell. 2003 Jun;3(6):589-601 [12842087.001]
  • [Cites] Lancet. 2003 Jun 28;361(9376):2217-25 [12842378.001]
  • [Cites] Clin Cancer Res. 2003 Jul;9(7):2394-9 [12855610.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Apr 2;93(7):2930-5 [8610145.001]
  • [Cites] Am J Pathol. 1996 Dec;149(6):1899-917 [8952526.001]
  • [Cites] Cancer Res. 1997 Apr 1;57(7):1294-300 [9102216.001]
  • [Cites] Br J Cancer. 1997;76(11):1410-5 [9400935.001]
  • [Cites] Cancer Res. 1998 Mar 1;58(5):1048-51 [9500469.001]
  • [Cites] J Bone Miner Res. 1998 Apr;13(4):581-9 [9556058.001]
  • [Cites] Cancer Res. 1998 May 1;58(9):1952-9 [9581838.001]
  • [Cites] Cell. 1998 May 1;93(3):411-22 [9590175.001]
  • [Cites] Gynecol Oncol. 1999 Mar;72(3):380-6 [10053110.001]
  • [Cites] Science. 1999 Apr 30;284(5415):808-12 [10221914.001]
  • [Cites] Genes Dev. 1999 Jun 1;13(11):1382-97 [10364156.001]
  • [Cites] Ann N Y Acad Sci. 1999 Jun 30;878:372-87 [10415742.001]
  • [Cites] Ann N Y Acad Sci. 1999 Jun 30;878:453-65 [10415748.001]
  • [Cites] J Natl Cancer Inst. 1995 Aug 16;87(16):1237-45 [7563170.001]
  • [Cites] Cold Spring Harb Symp Quant Biol. 2002;67:293-300 [12858552.001]
  • [Cites] Semin Oncol. 2003 Aug;30(4 Suppl 9):80-94 [12908139.001]
  • [Cites] Cancer Res. 2003 Aug 15;63(16):4862-71 [12941807.001]
  • [Cites] Life Sci. 2003 Sep 26;73(19):2413-20 [12954450.001]
  • [Cites] Cancer Res. 2003 Sep 1;63(17):5224-9 [14500349.001]
  • [Cites] Biochem Biophys Res Commun. 2003 Oct 24;310(3):816-23 [14550277.001]
  • [Cites] J Clin Invest. 2000 Apr;105(8):1045-7 [10772648.001]
  • (PMID = 15343380.001).
  • [ISSN] 0021-9738
  • [Journal-full-title] The Journal of clinical investigation
  • [ISO-abbreviation] J. Clin. Invest.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Diphosphonates; 0 / Imidazoles; 0 / Matrix Metalloproteinase Inhibitors; 0 / Vascular Endothelial Growth Factors; 6XC1PAD3KF / zoledronic acid; EC 3.4.24.35 / Matrix Metalloproteinase 9
  • [Other-IDs] NLM/ PMC514591
  •  go-up   go-down


5. Barnett AA, Haller JC, Cairnduff F, Lane G, Brown SB, Roberts DJ: A randomised, double-blind, placebo-controlled trial of photodynamic therapy using 5-aminolaevulinic acid for the treatment of cervical intraepithelial neoplasia. Int J Cancer; 2003 Mar 1;103(6):829-32
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A randomised, double-blind, placebo-controlled trial of photodynamic therapy using 5-aminolaevulinic acid for the treatment of cervical intraepithelial neoplasia.
  • Photodynamic therapy (PDT) using topical 5-aminolaevulinic acid (ALA) has been used to treat histologically confirmed cervical intraepithelial neoplasia (CIN-I and -I/II) in a randomised, double-blind, placebo-controlled protocol.
  • Fluorescence microscopy revealed that topical application of 3% ALA in Intrasite Gel to the cervix for 3 hr resulted in the accumulation of protoporphyrin IX in the cervical epithelium.
  • Treatment of CIN with ALA-PDT was well tolerated, with only 3/12 patients in the PDT arm (0/13 in the placebo arm) reporting any discomfort during illumination.
  • Histologic examination of the treated tissue following loop excision 3 months post-PDT indicated that 33% of patients had no evidence of CIN, 42% had no change in the grade of their disease, whilst 25% exhibited an apparent progression of disease.
  • There was no significant difference in response between the groups receiving ALA-PDT and those receiving placebo treatment.
  • [MeSH-major] Aminolevulinic Acid / therapeutic use. Cervical Intraepithelial Neoplasia / drug therapy. Photochemotherapy. Photosensitizing Agents / therapeutic use. Uterine Cervical Neoplasms / drug therapy
  • [MeSH-minor] Administration, Topical. Adult. Cervix Uteri / drug effects. Colposcopy. Double-Blind Method. Female. Humans. Image Processing, Computer-Assisted. Microscopy, Fluorescence. Protoporphyrins / metabolism

  • Genetic Alliance. consumer health - Cervical Intraepithelial Neoplasia.
  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2002 Wiley-Liss, Inc.
  • (PMID = 12516106.001).
  • [ISSN] 0020-7136
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial; Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Photosensitizing Agents; 0 / Protoporphyrins; 553-12-8 / protoporphyrin IX; 88755TAZ87 / Aminolevulinic Acid
  •  go-up   go-down


6. Cazorla E, Urgal A, Córdoba J, Boldó A, Marín M, Sánchez Gutiérrez M, Molina JM, Llixiona J: [Immunomodulatory treatment with beta-interferon in patients with cervical intraepithelial neoplasia and human papillomavirus infection: long-term follow-up]. Rev Esp Quimioter; 2005 Mar;18(1):26-31
MedlinePlus Health Information. consumer health - Cervix Disorders.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Immunomodulatory treatment with beta-interferon in patients with cervical intraepithelial neoplasia and human papillomavirus infection: long-term follow-up].
  • [Transliterated title] Tratamiento inmunomodulador con interferón beta en pacientes con neoplasia cervical intraepitelial e infección por virus del papiloma humano. Seguimiento a largo plazo.
  • The aim of this study was to evaluate the long-term efficacy of beta-interferon treatment in the management of cervical intraepithelial neoplasia associated with human papillomavirus (HPV) infection in a selected group of patients.
  • Thirty-nine patients who had histologically proven cervical intraepithelial neoplasia I or II with concurrent HPV infection were administered 27,000,000 IU of intramuscular beta-interferon.
  • An initial complete response rate of 75% was obtained, with a recurrence rate of 25%, cervical intraepithelial neoplasia with late manifestation was of higher grade.
  • Treatment interruption due to side-effects was not necessary.
  • While immunomodulatory treatment with beta-interferon has good long-term results in cervical intraepithelial neoplasia I/II treatment, wider randomized studies are required to obtain conclusive results.
  • [MeSH-major] Adjuvants, Immunologic / therapeutic use. Cervical Intraepithelial Neoplasia / complications. Cervical Intraepithelial Neoplasia / drug therapy. Interferon-beta / therapeutic use. Papillomavirus Infections / complications. Papillomavirus Infections / drug therapy. Uterine Cervical Diseases / complications. Uterine Cervical Diseases / drug therapy. Uterine Cervical Neoplasms / complications. Uterine Cervical Neoplasms / drug therapy
  • [MeSH-minor] Adult. Female. Follow-Up Studies. Humans. Middle Aged. Time Factors

  • Genetic Alliance. consumer health - Cervical Intraepithelial Neoplasia.
  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15915229.001).
  • [ISSN] 0214-3429
  • [Journal-full-title] Revista española de quimioterapia : publicación oficial de la Sociedad Española de Quimioterapia
  • [ISO-abbreviation] Rev Esp Quimioter
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Spain
  • [Chemical-registry-number] 0 / Adjuvants, Immunologic; 77238-31-4 / Interferon-beta
  •  go-up   go-down


7. Di Roma E, Parlavecchio E, Vettraino G, Corosu R: [CIN: multicentric study of therapeutic strategies]. Minerva Ginecol; 2001 Dec;53(6):379-2
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [CIN: multicentric study of therapeutic strategies].
  • [Transliterated title] CIN: studio multicentrico sulle strategie terapeutiche.
  • BACKGROUND: Cervical Intraepithelial Neoplasia (CIN) is a dysplastic lesion that precedes cervical cancer.
  • The diagnosis is made by colposcopic, cytologic and bioptic exams.
  • Therapy may be physical, pharmacological or surgical.
  • Our aim was to evaluate their therapeutic strategies for CIN and cervical condylomata.
  • We referred to SIGO 1999 guidelines for CIN therapy and to European guidelines for cervical condylomata therapy.
  • RESULTS: The centers used drugs more for HPV infections (57%) than for dysplasia (33%).
  • Drug therapy was used more in the past (66.67%).
  • Actually they prefer treating CIN I with electrocoagulation diathermy (DTC), CIN II with loop electrosurgical excision procedures (LEEP) or Laser, CIN III with cold knife conization or LEEP, cervical condylomata with laser or DTC.
  • CONCLUSIONS: The results show that the centers prefer physical therapy.
  • Therapeutic strategies comply with SIGO 1999 guidelines for therapy of CIN and with European guidelines for cervical condylomata partially.
  • [MeSH-major] Cervical Intraepithelial Neoplasia / therapy. Uterine Cervical Neoplasms / therapy
  • [MeSH-minor] Conization. Electrocoagulation. Electrosurgery. Female. Humans. Hysterectomy. Interferons / therapeutic use. Interviews as Topic. Italy. Laser Therapy. Practice Guidelines as Topic. Surveys and Questionnaires

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • International Agency for Research on Cancer - Screening Group. diagnostics - A practical manual on visual screening for cervical neoplasia .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11723421.001).
  • [ISSN] 0026-4784
  • [Journal-full-title] Minerva ginecologica
  • [ISO-abbreviation] Minerva Ginecol
  • [Language] ita
  • [Publication-type] Comparative Study; English Abstract; Journal Article; Multicenter Study
  • [Publication-country] Italy
  • [Chemical-registry-number] 9008-11-1 / Interferons
  •  go-up   go-down


8. Corona Gutierrez CM, Tinoco A, Navarro T, Contreras ML, Cortes RR, Calzado P, Reyes L, Posternak R, Morosoli G, Verde ML, Rosales R: Therapeutic vaccination with MVA E2 can eliminate precancerous lesions (CIN 1, CIN 2, and CIN 3) associated with infection by oncogenic human papillomavirus. Hum Gene Ther; 2004 May;15(5):421-31
International Agency for Research on Cancer - Screening Group. diagnostics - Planning and Implementing Cervical Cancer Prevention and Control Programs: A Manual for Managers .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Therapeutic vaccination with MVA E2 can eliminate precancerous lesions (CIN 1, CIN 2, and CIN 3) associated with infection by oncogenic human papillomavirus.
  • Human papillomavirus (HPV) infection is associated with cervical cancer.
  • Cervical cancer is a serious problem in developing countries because it is usually not detected at an early stage.
  • In a phase I/II clinical trial, we evaluated the potential use of the MVA E2 recombinant vaccinia virus to treat cervical intraepithelial neoplasia CIN 1, CIN 2, and CIN 3 lesions associated with human papillomavirus (HPV) infection.
  • Seventy-eight women with CIN 1-, CIN 2-, and CIN 3-grade lesions were treated with either an MVA E2 recombinant virus vaccine or with cryosurgery.
  • The type of immune response after MVA E2 injection was determined by measuring antibody titers against MVA E2 virus and the E2 protein, and by the presence of cytotoxic activity against cancer cells bearing papillomavirus DNA.
  • Thirty-four of 36 patients showed complete elimination of precancerous lesions after treatment with the MVA E2 vaccine.
  • In two patients, precancerous lesions were reduced from grade CIN 3 to CIN 1.
  • Three other patients presented isolated koilocytes after treatment with MVA E2.
  • Colposcopy revealed no lesions in 85% of patients, and only small aceto-white spots were detected in 15% of patients after treatment with MVA E2.
  • All patients developed antibodies against the MVA E2 vaccine, and vaccination generated a specific cytotoxic response against HPV-transformed cells.
  • Furthermore, 50% of patients showed no evidence of papillomavirus after treatment with MVA E2, while the remaining 50% showed persistence of HPV DNA, but at approximately only 10% of the original viral load.
  • Cryosurgery eliminated the lesions of CIN 1 in all patients, but patients so treated did not develop cytotoxic activity against cancer cells.
  • These results show that therapeutic vaccination with MVA E2 vaccine is an excellent prospective means for stimulating the immune system and causing the regression of precancerous CIN 1, CIN 2, and CIN 3 lesions when the vaccine is given locally.
  • [MeSH-major] Cervical Intraepithelial Neoplasia / drug therapy. Uterine Cervical Neoplasms / prevention & control. Vaccines, DNA / therapeutic use. Vaccinia virus / immunology
  • [MeSH-minor] Adult. Cell Transformation, Viral. Colposcopy. Cytotoxicity Tests, Immunologic. Enzyme-Linked Immunosorbent Assay. Female. Humans. Middle Aged. Papillomaviridae / immunology. Papillomavirus Infections / blood. Patient Selection. Treatment Outcome. Viral Load

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15144573.001).
  • [ISSN] 1043-0342
  • [Journal-full-title] Human gene therapy
  • [ISO-abbreviation] Hum. Gene Ther.
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Vaccines, DNA
  •  go-up   go-down


9. Cheng AL, Hsu CH, Lin JK, Hsu MM, Ho YF, Shen TS, Ko JY, Lin JT, Lin BR, Ming-Shiang W, Yu HS, Jee SH, Chen GS, Chen TM, Chen CA, Lai MK, Pu YS, Pan MH, Wang YJ, Tsai CC, Hsieh CY: Phase I clinical trial of curcumin, a chemopreventive agent, in patients with high-risk or pre-malignant lesions. Anticancer Res; 2001 Jul-Aug;21(4B):2895-900
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • 1) recently resected urinary bladder cancer;.
  • 3) uterine cervical intraepithelial neoplasm (CIN);.
  • If no toxicity > or = grade II was noted in at least 3 successive patients, the dose was then escalated to another level in the order of 1,000, 2,000, 4,000, 8,000, and 12,000 mg/day.
  • There was no treatment-related toxicity up to 8,000 mg/day.
  • Beyond 8,000 mg/day, the bulky volume of the drug was unacceptable to the patients.
  • One of 4 patients with CIN and 1 of 7 patients with oral leucoplakia proceeded to develop frank malignancies in spite of curcumin treatment.
  • In contrast, histologic improvement of precancerous lesions was seen in 1 out of 2 patients with recently resected bladder cancer, 2 out of 7 patients of oral leucoplakia, 1 out of 6 patients of intestinal metaplasia of the stomach, I out of 4 patients with CIN and 2 out of 6 patients with Bowen's disease.
  • Our results also suggest a biologic effect of curcumin in the chemoprevention of cancer.
  • [MeSH-major] Anticarcinogenic Agents / therapeutic use. Bowen's Disease / drug therapy. Carcinoma, Transitional Cell / drug therapy. Cervical Intraepithelial Neoplasia / drug therapy. Curcumin / therapeutic use. Leukoplakia, Oral / drug therapy. Precancerous Conditions / drug therapy. Skin Neoplasms / drug therapy. Stomach / pathology. Stomach Neoplasms / prevention & control. Urinary Bladder Neoplasms / drug therapy. Uterine Cervical Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Arsenicals / adverse effects. Dose-Response Relationship, Drug. Female. Humans. Male. Metaplasia. Middle Aged. Neoplasm Recurrence, Local / prevention & control. Prospective Studies. Risk. Treatment Outcome


10. Sikorski M, Zrubek H: Long-term follow-up of patients treated with recombinant human interferon gamma for cervical intraepithelial neoplasia. Int J Gynaecol Obstet; 2003 Aug;82(2):179-85
MedlinePlus Health Information. consumer health - Cervical Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term follow-up of patients treated with recombinant human interferon gamma for cervical intraepithelial neoplasia.
  • OBJECTIVES: The immediate results of interferon gamma (IFN-gamma) treatment in the management of cervical intraepithelial neoplasia (CIN) have been described.
  • However, little is known of the long-term results of this conservative treatment and we aimed to assess them.
  • METHODS: We conducted a 5-year follow-up of 13 women with either complete response to intracervical administration of 6,000,000 IU of IFN-gamma (remission from human papilloma virus-induced CIN occurred in nine cases) or partial response (a lower grade of CIN and/or HPV clearance was achieved in four cases).
  • We found three cases of relapse of stage 1 CIN (CIN I), for a recurrence rate of 33.3%, and three cases of complete remission in four subjects with initial diagnosis of partial response.
  • This allowed us to assess the overall lesion-free rate at 53% for the entire group of patients who had CIN I and CIN II treated with IFN-gamma.
  • CONCLUSIONS: Immunomodulation therapy with IFN-gamma has a high long-term efficacy; however, it is inferior to that of surgery.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Cervical Intraepithelial Neoplasia / drug therapy. Interferon-gamma / therapeutic use. Uterine Cervical Neoplasms / drug therapy
  • [MeSH-minor] Adult. Colposcopes. Female. Follow-Up Studies. Humans. Middle Aged. Papanicolaou Test. Recombinant Proteins. Treatment Outcome. Vaginal Smears

  • Genetic Alliance. consumer health - Cervical Intraepithelial Neoplasia.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12873779.001).
  • [ISSN] 0020-7292
  • [Journal-full-title] International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics
  • [ISO-abbreviation] Int J Gynaecol Obstet
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Recombinant Proteins; 82115-62-6 / Interferon-gamma
  •  go-up   go-down


11. Soergel P, Wang X, Stepp H, Hertel H, Hillemanns P: Photodynamic therapy of cervical intraepithelial neoplasia with hexaminolevulinate. Lasers Surg Med; 2008 Nov;40(9):611-5
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Photodynamic therapy of cervical intraepithelial neoplasia with hexaminolevulinate.
  • BACKGROUND AND OBJECTIVE: CIN is a disease of women in their reproductive years, and treatment includes excisional techniques with increased risk of preterm deliveries.
  • Photodynamic therapy (PDT) using topical precursor of photoactive porphyrins may be a non-invasive alternative with minimal side effects.
  • This study assessed the feasibility and response rate of PDT with hexaminolevulinate (HAL) in cervical intraepithelial neoplasia (CIN) and human papillomavirus (HPV) infection.
  • STUDY DESIGN/MATERIALS AND METHODS: Twenty four patients with a CIN 2 or 3 or a persistent CIN 1 and a positive high-risk HPV-DNA test were included.
  • Each patient had gynaecologic examination including cervical cytology, HPV DNA testing, colposcopy and biopsy.
  • Ten milliliters of HAL-thermogel (10 mM) were topically applied to the cervix for 3-5 hours, followed by 1,000 seconds of illumination of both ecto- and endocervical canal with red coherent light (wave length 633 nm) using a PDT laser and a special light catheter.
  • RESULTS: Seven, 10, and 7 patients had a CIN 1, 2, or 3, respectively.
  • Treatment could be accomplished in all cases and no severe side effects were encountered.
  • Fifteen out of the 24 patients had a complete response (15/24 = 63%) and a HPV remission 6 months after 1-3 treatments.
  • The remission rates were 71%, 50%, and 71% for CIN 1, 2 and 3.
  • CONCLUSION: HAL PDT seems to be a non-invasive, repeatable procedure for CIN and cervical HPV infection with minimal side effects which can be easily performed on outpatient basis.
  • [MeSH-major] Aminolevulinic Acid / analogs & derivatives. Cervical Intraepithelial Neoplasia / drug therapy. Photochemotherapy. Photosensitizing Agents / therapeutic use. Uterine Cervical Neoplasms / drug therapy
  • [MeSH-minor] Adult. Feasibility Studies. Female. Humans. Papillomavirus Infections / drug therapy. Papillomavirus Infections / pathology. Treatment Outcome. Young Adult


12. Kiatpongsan S, Niruthisard S, Mutirangura A, Trivijitsilp P, Vasuratna A, Chaithongwongwatthana S, Lertkhachonsuk R: Role of human papillomavirus DNA testing in management of women with atypical squamous cells of undetermined significance. Int J Gynecol Cancer; 2006 Jan-Feb;16(1):262-5
International Agency for Research on Cancer - Screening Group. diagnostics - A practical manual on visual screening for cervical neoplasia .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • To find the sensitivity, specificity, and positive and negative predictive values of the high-risk group human papillomavirus (HPV) DNA testing as a triage tool to detect high-grade squamous intraepithelial lesions (HSILs, ie, cervical intraepithelial neoplasia [CIN] 2 or worse) in women with a cytologic smear showing atypical squamous cells of undetermined significance (ASC-US).
  • Cervical cell samplings were done by cervical cytobrush technique and tested for high-risk group HPV with the Hybrid Capture 2 (HC2) test.
  • Then cervicographs were taken before colposcopic-directed cervical biopsies were done.
  • Of the 90 ASC-US cases enrolled, the pathologic results were normal in 30.0%, squamous metaplasia in 16.7%, CIN 1 in 37.8%, CIN 2 in 1.1%, CIN 3 in 11.1%, and microinvasive cervical carcinoma in 3.3%.
  • The prevalence of HSILs and the prevalence of high-risk HPV detection were 15.6% and 38.9%, respectively.
  • Using pathologic results from cervical biopsy as the gold standard, the HC2 has the sensitivity, specificity, and positive and negative predictive values of 85.7%, 69.7%, 34.3%, and 96.4%, respectively, to detect HSILs.
  • High-risk group HPV detection can be used as an additional triage test to detect HSILs in women having ASC-US with high sensitivity and negative predictive value.
  • [MeSH-major] Carcinoma, Squamous Cell / virology. Cervical Intraepithelial Neoplasia / virology. DNA, Viral / analysis. Papillomaviridae / isolation & purification. Uterine Cervical Neoplasms / virology
  • [MeSH-minor] Adolescent. Adult. Biopsy, Needle. Cohort Studies. DNA Probes, HPV. Female. Humans. Immunohistochemistry. Middle Aged. Papillomavirus Infections / diagnosis. Papillomavirus Infections / drug therapy. Risk Assessment. Sensitivity and Specificity. Thailand. Triage

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16445642.001).
  • [ISSN] 1048-891X
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA Probes, HPV; 0 / DNA, Viral
  •  go-up   go-down


13. Palomba M, Melis GB: Oral use of interferon therapy in cervical human papillomavirus infection. Clin Ter; 2000;151(1 Suppl 1):59-61
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Oral use of interferon therapy in cervical human papillomavirus infection.
  • The efficacy and the optimal dose of systemic alpha-interferon treatment of genital human papillomavirus infection is now under discussion because of high cost, low compliance and systemic toxicity of this drug.
  • Recent studies seem to suggest that natural alpha-interferon may also have antiviral efficacy in humans after oral administration of low doses of the drug.
  • Low doses (150U tid for 8 weeks) of the drug were administered to 12 patients with mild cervical dysplasia and human papillomavirus infection.
  • A significantly higher proportion of Interferon treated subjects showed a colposcopic and histological regression of the lesion after months of treatment in comparison with 9 placebo treated patients (75% vs 30%) without major side effects.
  • These results seem to justify wider evaluations of this approach to Interferon treatment characterized by lower costs and fewer side effects in comparison with traditional systemic high dose treatment of alpha Interferon.
  • [MeSH-major] Antiviral Agents / administration & dosage. Interferon-alpha / administration & dosage. Papillomaviridae. Papillomavirus Infections / drug therapy. Tumor Virus Infections / drug therapy. Uterine Cervical Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10876967.001).
  • [ISSN] 0009-9074
  • [Journal-full-title] La Clinica terapeutica
  • [ISO-abbreviation] Clin Ter
  • [Language] eng; ita
  • [Publication-type] Clinical Trial; Controlled Clinical Trial; Journal Article
  • [Publication-country] ITALY
  • [Chemical-registry-number] 0 / Antiviral Agents; 0 / Interferon-alpha
  •  go-up   go-down


14. Ou KY, Chen YC, Hsu SC, Tsai EM: Topical vaginal oestrogen cream used for treatment of burn injury of vaginal mucosa after misapplication of 100% acetic acid in a perimenopausal woman: a case report. Aust N Z J Obstet Gynaecol; 2007 Aug;47(4):345-6
Hazardous Substances Data Bank. ACETIC ACID .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Topical vaginal oestrogen cream used for treatment of burn injury of vaginal mucosa after misapplication of 100% acetic acid in a perimenopausal woman: a case report.
  • BACKGROUND: Three to five per cent acetic acid is commonly used in the field of gynaecology for colposcopic examinations of the cervix.
  • CASE: A perimenopausal woman was treated with acetic acid for abnormal Pap smear report (cervical intraepithelial neoplasia 1).
  • [MeSH-major] Acetic Acid / adverse effects. Burns, Chemical / drug therapy. Estradiol Congeners / administration & dosage. Indicators and Reagents / adverse effects. Medication Errors

  • MedlinePlus Health Information. consumer health - Medication Errors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17627694.001).
  • [ISSN] 0004-8666
  • [Journal-full-title] The Australian & New Zealand journal of obstetrics & gynaecology
  • [ISO-abbreviation] Aust N Z J Obstet Gynaecol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Estradiol Congeners; 0 / Indicators and Reagents; 0 / Vaginal Creams, Foams, and Jellies; Q40Q9N063P / Acetic Acid
  •  go-up   go-down


15. Heard I, Tassie JM, Kazatchkine MD, Orth G: Highly active antiretroviral therapy enhances regression of cervical intraepithelial neoplasia in HIV-seropositive women. AIDS; 2002 Sep 6;16(13):1799-802
HIV InSite. treatment guidelines - Human Herpesvirus-8 .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Highly active antiretroviral therapy enhances regression of cervical intraepithelial neoplasia in HIV-seropositive women.
  • OBJECTIVE: This study was undertaken to investigate the impact of highly active antiretroviral therapy (HAART) on the regression of cervical intraepithelial neoplasia (CIN) in HIV-infected women.
  • DESIGN: Prospective study of 168 HIV-infected women with evidence of CIN until regression to a lower grade or to normality (end-point) or until surgical treatment or last visit.
  • The probability of CIN regression was calculated using survival analysis.
  • HAART was entered as a time-dependent covariate according to the date of first prescription.
  • RESULTS: Regression of CIN was observed in 67 (39.9%) women.
  • The probability of regression at 12 months was significantly higher for high-grade CIN [23.8%; 95% confidence interval (CI), 14.2-33.5] than for low-grade lesions (14.8%; 95% CI, 7.0-22.6) (P = 0.04).
  • The risk of regression of CIN was twice as high in women receiving HAART as compared with women not receiving HAART (relative hazard of regression, 1.93; 95% CI, 1.14-3.29).
  • CONCLUSION: The positive impact of HAART on CIN regression may be associated with some restoration of specific immune reactivity.
  • [MeSH-major] Antiretroviral Therapy, Highly Active. Cervical Intraepithelial Neoplasia / drug therapy. HIV Seropositivity / complications. Uterine Cervical Neoplasms / drug therapy
  • [MeSH-minor] Adult. Female. Humans. Middle Aged. Prospective Studies. Treatment Outcome


16. Helm CW, Lorenz DJ, Meyer NJ, Rising WR, Wulff JL: Retinoids for preventing the progression of cervical intra-epithelial neoplasia. Cochrane Database Syst Rev; 2007;(4):CD003296
MedlinePlus Health Information. consumer health - Cervical Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Retinoids for preventing the progression of cervical intra-epithelial neoplasia.
  • BACKGROUND: Invasive cervical carcinoma is preceded by a precancerous phase, cervical intra-epithelial neoplasia (CIN), which can be detected on cervical smears and confirmed by colposcopy and biopsy.
  • Moderate and severe intra-epithelial neoplasia (CIN2 and CIN3) are treated mainly with surgery to prevent progression to invasive carcinoma.
  • Medical methods of preventing the progression or inducing regression of CIN are needed.
  • Retinoids are potent modulators of epithelial cell growth and differentiation and may have potential for the treatment of CIN.
  • OBJECTIVES: To ascertain whether retinoids can cause regression or prevent progression of CIN.
  • SEARCH STRATEGY: Cochrane Gynaecological Cancer Review Group's Specialised Register and Non-Trials Database, Cochrane Central Register of Controlled Trials (CENTRAL) (Issue 2,2007),MEDLINE and EMBASE (June 2007).
  • SELECTION CRITERIA: Randomized controlled trials (RCTs) and non-RCTs of retinoids for treating CIN in women.
  • Two studies examined the effect on CIN2 and CIN3 of retinoids N-(4-hydroxyphenyl)retinamide (fenretinide) (Follen 2001) and 9-cis-retinoic acid (aliretinoin) (Alvarez 2003) given orally and two examined the effect of all-trans-retinoic acid given topically to the cervix (Meyskens 1994; Ruffin 2004).
  • The fifth study investigated the use of 13-cis-retinoic acid (isotretinoin) given orally in HIV positive patients with CIN1 and condyloma (Robinson 2002).Four studies reported no significant effect of retinoids on the progression to higher grades of CIN, whilst the fifth did not report data on progression.
  • In general, the retinoid medications were well tolerated.
  • Retinoids are not effective at preventing progression of CIN of any grade.
  • At the doses given and duration of treatment studied, the retinoids were reasonably well-tolerated.
  • [MeSH-major] Anticarcinogenic Agents / therapeutic use. Cervical Intraepithelial Neoplasia / drug therapy. Uterine Cervical Neoplasms / drug therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [UpdateIn] Cochrane Database Syst Rev. 2013;6:CD003296 [23740788.001]
  • (PMID = 17943787.001).
  • [ISSN] 1469-493X
  • [Journal-full-title] The Cochrane database of systematic reviews
  • [ISO-abbreviation] Cochrane Database Syst Rev
  • [Language] eng
  • [Publication-type] Journal Article; Meta-Analysis; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Anticarcinogenic Agents; 0 / Retinoids
  • [Number-of-references] 53
  •  go-up   go-down


17. Soncini E, Zoncada A, Condemi V, Antoni AD, Bocchialini E, Soregotti P: Reduction of the risk of cervical intraepithelial neoplasia in HIV-infected women treated with highly active antiretroviral therapy. Acta Biomed; 2007;78(1):36-40
International Agency for Research on Cancer - Screening Group. diagnostics - Planning and Implementing Cervical Cancer Prevention and Control Programs: A Manual for Managers .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Reduction of the risk of cervical intraepithelial neoplasia in HIV-infected women treated with highly active antiretroviral therapy.
  • BACKGROUND AND AIM OF THE WORK: The purpose of our study was to determine whether highly active antiretroviral therapy (HAART) reduces the onset of cervical intraepithelial neoplasia (CIN) in HIV-positive women.
  • METHODS: The study was designed to assess CIN incidence in a cohort of 101 HIV-positive women and to evaluate its relationship with ongoing antiretroviral therapy.
  • If any abnormalities were reported, the patients underwent targeted biopsy with histological confirmation of the diagnosis.
  • RESULTS: During the follow-up period, 38 patients (37.6%) developed histologically verified CIN, including low-grade CIN in seven patients (6.9%) and high-grade CIN in 31 patients (30.4%).
  • Over the study period, 43 patients (42.6%) were treated with HAART for at least 6 months, the average duration of treatment being 37 months.
  • Analysis of HAART efficacy in preventing CIN onset, determined by the Cox regression model with a time-dependent covariate adjusted for the CD4 level at the first visit, showed that HAART significantly reduced the risk of developing CIN (hazard ratio, 0.3; p = 0.004).
  • CONCLUSION: HIV-positive patients present a high incidence of CIN and of high-grade CIN in particular.
  • HAART exhibits a protective action against the onset of cervical lesions.
  • [MeSH-major] Antiretroviral Therapy, Highly Active. Cervical Intraepithelial Neoplasia / prevention & control. HIV Infections / drug therapy. Uterine Cervical Neoplasms / prevention & control


18. Hefler LA, Grimm C, Speiser P, Sliutz G, Reinthaller A: The cyclooxygenase-2 inhibitor rofecoxib (Vioxx) in the treatment of cervical dysplasia grade II-III A phase II trial. Eur J Obstet Gynecol Reprod Biol; 2006 Apr 1;125(2):251-4
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The cyclooxygenase-2 inhibitor rofecoxib (Vioxx) in the treatment of cervical dysplasia grade II-III A phase II trial.
  • OBJECTIVE: To determine whether the cyclooxygenase (COX)-2 inhibitor rofecoxib increases the regression rates of cervical intraepithelial neoplasia (CIN) grade II and III.
  • STUDY DESIGN: A prospective, randomized, placebo-controlled, double-blind study with rofecoxib 25 mg daily for 6 [corrected] months as active treatment for patients with CIN II and III was started in May 2004 [corrected] and was halted after rofecoxib withdrawal in October 2004 [corrected] RESULTS: A total of 16 patients with CIN II (n=9) and CIN III (n=7) were included in our study.
  • Regression rates in the rofecoxib and placebo arm were statistically not significant (25% versus 12.5%) after a mean of 87 (46.3) days of treatment.
  • No severe side effects were noted during the therapy; no dropouts were recorded.
  • CONCLUSION: A conservative treatment of CIN II and III is feasible.
  • Inhibitors of COX, especially COX-2, were seen as candidates for cancer chemoprevention.
  • The results obtained should be added to those already published for planning future studies on medical therapies for high grade CIN.
  • [MeSH-major] Cervical Intraepithelial Neoplasia / drug therapy. Cyclooxygenase 2 Inhibitors / therapeutic use. Lactones / therapeutic use. Sulfones / therapeutic use. Uterine Cervical Dysplasia / drug therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Eur J Obstet Gynecol Reprod Biol. 2006 Nov;129(1):100
  • (PMID = 16188370.001).
  • [ISSN] 0301-2115
  • [Journal-full-title] European journal of obstetrics, gynecology, and reproductive biology
  • [ISO-abbreviation] Eur. J. Obstet. Gynecol. Reprod. Biol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study; Randomized Controlled Trial
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Cyclooxygenase 2 Inhibitors; 0 / Lactones; 0 / Sulfones; 0QTW8Z7MCR / rofecoxib
  •  go-up   go-down


19. Keefe KA, Tadir Y, Tromberg B, Berns M, Osann K, Hashad R, Monk BJ: Photodynamic therapy of high-grade cervical intraepithelial neoplasia with 5-aminolevulinic acid. Lasers Surg Med; 2002;31(4):289-93
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Photodynamic therapy of high-grade cervical intraepithelial neoplasia with 5-aminolevulinic acid.
  • BACKGROUND AND OBJECTIVES: To determine the safety and efficacy of 5-aminolevulinic acid (ALA) as a topically applied photosensitizer for photodynamic therapy (PDT) of cervical intraepithelial neoplasia (CIN).
  • STUDY DESIGNS/MATERIALS AND METHODS: Forty women, who were at least 18 years old with persistent biopsy-proven CIN 2 and CIN 3 within the previous 3 months of enrollment, underwent PDT in a phase I and II design.
  • ALA was placed in a cervical cap fitted to the cervix.
  • Success was defined as the absence of CIN on Pap smear or colposcopic examination at 12-months.
  • Sixty percent had CIN 3 and 40% CIN 2.
  • Three patients progressed from CIN 2 to CIN 3.
  • Toxicity was tolerable and only consisted of spotting, vaginal discharge, mild cramping, and vaginal warmth.
  • CONCLUSIONS: PDT at this light and ALA dose is well tolerated but has minimal activity in the treatment of CIN 2 and CIN 3.
  • [MeSH-major] Aminolevulinic Acid / therapeutic use. Cervical Intraepithelial Neoplasia / drug therapy. Photochemotherapy / adverse effects. Photosensitizing Agents / therapeutic use. Uterine Cervical Neoplasms / drug therapy
  • [MeSH-minor] Adult. Female. Follow-Up Studies. Humans. Outcome Assessment (Health Care). Severity of Illness Index. Time Factors

  • Genetic Alliance. consumer health - Cervical Intraepithelial Neoplasia.
  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • COS Scholar Universe. author profiles.
  • International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2002 Wiley-Liss, Inc.
  • (PMID = 12355576.001).
  • [ISSN] 0196-8092
  • [Journal-full-title] Lasers in surgery and medicine
  • [ISO-abbreviation] Lasers Surg Med
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / 1K23CA87558; United States / NCI NIH HHS / CA / CA-32248
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Photosensitizing Agents; 88755TAZ87 / Aminolevulinic Acid
  •  go-up   go-down


20. Luxton JC, Nath R, Derias N, Herbert A, Shepherd PS: Human papillomavirus type 16-specific T cell responses and their association with recurrence of cervical disease following treatment. J Gen Virol; 2003 May;84(Pt 5):1063-70
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Human papillomavirus type 16-specific T cell responses and their association with recurrence of cervical disease following treatment.
  • Human papillomavirus type 16 (HPV-16) L1- and E7-specific T cell responses were measured in 58 women with abnormal cervical cytology in a prospective study.
  • On recruitment, patients responded most frequently and with the highest numbers of responding cells to the L1 region aa 311-345 and this response was significantly associated with the presence of cervical disease (P=0.041).
  • Responses to the L1 peptide aa 281-295 were significantly higher in patients with CIN III than in those with HPV/CIN I or CIN II lesions (P=0.027).
  • The E7 region aa 70-98 was the most immunogenic in patients with squamous intraepithelial lesions of the cervix (SIL) but the responses detected were not significantly higher than in patients without SIL.
  • Following treatment, the T cell response profiles of patient groups did not change significantly.
  • Recurrence of disease was associated with T cell responses to the E7 region aa 70-98 at the patient's first clinic visit (P=0.017).
  • [MeSH-major] Capsid Proteins. Cervical Intraepithelial Neoplasia / physiopathology. Papillomaviridae / immunology. T-Lymphocytes / immunology. Uterine Cervical Diseases / drug therapy. Uterine Cervical Diseases / physiopathology. Uterine Cervical Neoplasms / physiopathology

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • MedlinePlus Health Information. consumer health - Cervix Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12692269.001).
  • [ISSN] 0022-1317
  • [Journal-full-title] The Journal of general virology
  • [ISO-abbreviation] J. Gen. Virol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Capsid Proteins; 0 / L1 protein, Human papillomavirus type 16; 0 / Oncogene Proteins, Viral; 0 / Papillomavirus E7 Proteins; 0 / Peptides; 0 / oncogene protein E7, Human papillomavirus type 16
  •  go-up   go-down


21. Fusté P, Santamaría X, Carreras R: [New therapeutic strategies for human papillomavirus related anogenital lesions in HIV patients: highly active antiretroviral therapy and HPV vaccines]. Med Clin (Barc); 2008 Jun 7;131(1):30-4
MedlinePlus Health Information. consumer health - HIV/AIDS Medicines.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [New therapeutic strategies for human papillomavirus related anogenital lesions in HIV patients: highly active antiretroviral therapy and HPV vaccines].
  • [Transliterated title] Nuevas estrategias terapéuticas para las lesiones anogenitales relacionadas con el virus del papiloma humano en pacientes con infección por el VIH: tratamiento antirretroviral de gran actividad y vacunas anti-VPH.
  • This review focuses on the recent therapeutic advances that may affect the management of neoplastic anogenital human papillomavirus (HPV)-related lesions in human immunodeficiency virus patients: highly active antiretroviral therapy (HAART) and HPV vaccines.
  • HAART shows limited benefit on the incidence of high grade intraepithelial lesions and cancer in cervix, vulva and anus.
  • On the other hand, it seems to raise discretely the spontaneous regression rates of cervical low grade lesions -cervical intraepithelial neoplasia (CIN) grade I- and condylomas, as well as the regression after treatment of CIN II-III.
  • The benefit of HAART in squamous intraepithelial lesion seems to be modest, mostly due to the improvement of the immune status.
  • Second generation vaccines, still to be developed, might better adapt the specific needs of these patients.
  • [MeSH-major] Antiretroviral Therapy, Highly Active. Anus Neoplasms / complications. Anus Neoplasms / drug therapy. Genital Neoplasms, Female / complications. Genital Neoplasms, Female / drug therapy. Genital Neoplasms, Male / complications. Genital Neoplasms, Male / drug therapy. HIV Infections / complications. HIV Infections / drug therapy. Papillomavirus Infections / complications. Papillomavirus Infections / drug therapy. Papillomavirus Vaccines / therapeutic use

  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • MedlinePlus Health Information. consumer health - HIV/AIDS in Women.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18582422.001).
  • [ISSN] 0025-7753
  • [Journal-full-title] Medicina clínica
  • [ISO-abbreviation] Med Clin (Barc)
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Spain
  • [Chemical-registry-number] 0 / Papillomavirus Vaccines
  • [Number-of-references] 80
  •  go-up   go-down


22. Karp CL, Moore JK, Rosa RH Jr: Treatment of conjunctival and corneal intraepithelial neoplasia with topical interferon alpha-2b. Ophthalmology; 2001 Jun;108(6):1093-8
MedlinePlus Health Information. consumer health - Corneal Disorders.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of conjunctival and corneal intraepithelial neoplasia with topical interferon alpha-2b.
  • OBJECTIVE: To evaluate the role of topical interferon alfa-2b (IFNalpha2b) in the treatment of conjunctival and corneal intraepithelial neoplasia (CIN).
  • PARTICIPANTS: Five patients with histologically proven CIN or recurrences of proven CIN were studied prospectively.
  • INTERVENTION: After histologic confirmation, patients were given topical recombinant IFNalpha2b (INTRON A, Schering Plough, Kenilworth, NJ) 1 million IU/ml four times a day.
  • RESULTS: All patients had complete resolution of the CIN lesion on IFNalpha2b.
  • The mean time to clinical resolution was 11.6 weeks (range, 4-22 weeks).
  • One patient had a clinical recurrence of his corneal CIN 1 year after tumor resolution.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Carcinoma in Situ / drug therapy. Conjunctival Neoplasms / drug therapy. Corneal Diseases / drug therapy. Interferon-alpha / therapeutic use
  • [MeSH-minor] Administration, Topical. Adult. Aged. Eye Neoplasms / drug therapy. Eye Neoplasms / pathology. Female. Humans. Male. Middle Aged. Neoplasm Recurrence, Local. Ophthalmic Solutions. Recombinant Proteins. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11382635.001).
  • [ISSN] 0161-6420
  • [Journal-full-title] Ophthalmology
  • [ISO-abbreviation] Ophthalmology
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Interferon-alpha; 0 / Ophthalmic Solutions; 0 / Recombinant Proteins; 99210-65-8 / interferon alfa-2b
  •  go-up   go-down


23. Sikorski M, Bieda T, Bobek M, Zrubek H: Dynamics of cervical langerhans cell counts in the course of HPV-positive CIN treatment with the use of human recombinant interferon gamma. Eur J Gynaecol Oncol; 2005;26(3):294-8
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dynamics of cervical langerhans cell counts in the course of HPV-positive CIN treatment with the use of human recombinant interferon gamma.
  • OBJECTIVES: Langerhans cells play a pivotal role as professional antigens presenting cells in cervical epithelium, thus changes in their density or/and function may profoundly influence the proper activation of the afferent arm of immune response in cases of HPV-related intraepithelial lesions.
  • AIM OF THE STUDY: Assessment of intraepithelial Langerhans cell count changes in CIN I/CIN II after human recombinant interferon gamma (IFNgamma) application and correlation with clinical outcome.
  • MATERIAL & METHODS: The present study is a part of prospective trial on IFNgamma application in the treatment of CIN I/CINII associated with high-risk HPV infection.
  • Seventeen subjects underwent uniform IFNgamma treatment (four intracervical injections in a two-day interval for a total dose of 6,000,000 IU).
  • Langerhans cells were stained within cervical punch biopsy specimens with the use of polyclonal anti-S-100 antibody according to the three-step indirect peroxidase protocol, and their mean count calculated for the following groups: before IFNgamma treatment launching, immediately after completion of the treatment, and after two months of follow-up.
  • RESULTS: The analysis revealed a rapid and significant increase in Lagerhans' cell count immediately after treatment completion (21.17/mm2 and 25.94/mm2, respectively, at p = 0.019) which further increased in the group of complete response (in 9 subjects; 32.22/mm2).
  • CONCLUSION: Our data strongly support the observation from static studies suggesting that regression of HPV-related cervical lesions is associated with increased density of epithelial Langerhans cells.
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Cervical Intraepithelial Neoplasia / drug therapy. Interferon-gamma / administration & dosage. Langerhans Cells / immunology. Uterine Cervical Neoplasms / drug therapy
  • [MeSH-minor] Adult. Antiviral Agents / administration & dosage. Cell Count. Cervix Uteri / drug effects. Cervix Uteri / immunology. Female. Humans. Injections, Intralesional. Middle Aged. Papillomaviridae. Papillomavirus Infections / drug therapy. Papillomavirus Infections / immunology. Recombinant Proteins. Remission Induction. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15991530.001).
  • [ISSN] 0392-2936
  • [Journal-full-title] European journal of gynaecological oncology
  • [ISO-abbreviation] Eur. J. Gynaecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Antiviral Agents; 0 / Recombinant Proteins; 82115-62-6 / Interferon-gamma
  •  go-up   go-down


24. Ruan YH, Wei WL, Zhang HX, Liang ZN, Liu BY, Chen Y: [Comparison and analysis of expression of c-myc and p16 in cervical carcinoma]. Ai Zheng; 2003 Jun;22(6):602-6
International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Comparison and analysis of expression of c-myc and p16 in cervical carcinoma].
  • It is still unclear whether abnormal expression of c-myc and p16 cooperate in the occurrence and progression of cervical carcinoma, and whether there exists a connection between the expression of two genes and the chemotherapy response of cervical carcinoma.
  • This study was designed to investigate the correlation between the expression of c-myc and p16 and their roles in the genesis and development of the uterine cervical carcinoma and chemotherapy response.
  • METHODS: Using in situ hybridization, 37 cases of cervical carcinoma (including 11 cases after chemotherapy), 21 cases of precancerous lesion and 5 cases of normal cervix were observed for c-myc and p16 mRNA with dig-labeled probes.
  • RESULTS: The positive expression rates of p16 in normal cervix,CIN (cervical intraepithelial neoplasia) and cervical carcinoma were 100%, 71.4%, and 21.6%, respectively (P=0.0001), whereas the expression rates of c-myc were 0%, 42.9%, and 75.7% (P=0.0011), respectively.
  • The expression of positive signals of c-myc increased with the increase of malignant degree, and the positive signals in CIN III were also higher than that in CIN II and CIN I.
  • The expression rates of c-myc were decreased in cervical carcinoma after chemotherapy.
  • Expression of p16 and c-myc showed no significant difference between effectual and ineffectual chemotherapy groups.
  • CONCLUSION: Both over expression of c-myc and descended expression of p16 may play an important role in the genesis and development of uterine cervical carcinoma.
  • The increased expression of c-myc in different grade CIN suggests that carcinogenesis of cervix be progressive.
  • [MeSH-major] Cervical Intraepithelial Neoplasia / genetics. Genes, myc. Uterine Cervical Neoplasms / genetics
  • [MeSH-minor] Female. Genes, p16. Humans. Neoplasm Staging. RNA, Messenger / analysis

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12948409.001).
  • [Journal-full-title] Ai zheng = Aizheng = Chinese journal of cancer
  • [ISO-abbreviation] Ai Zheng
  • [Language] chi
  • [Publication-type] Comparative Study; English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / RNA, Messenger
  •  go-up   go-down


25. Snoeck R, Noel JC, Muller C, De Clercq E, Bossens M: Cidofovir, a new approach for the treatment of cervix intraepithelial neoplasia grade III (CIN III). J Med Virol; 2000 Feb;60(2):205-9
Hazardous Substances Data Bank. CIDOFOVIR .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cidofovir, a new approach for the treatment of cervix intraepithelial neoplasia grade III (CIN III).
  • Cervix intraepithelial neoplasia grade III (CIN III) is an intraepithelial proliferative process with different levels of severity depending on both the extension of the proliferation in the epithelium and the presence of cellular atypia.
  • The results of a preliminary study are described on the local application of cidofovir, an acyclic nucleoside phosphonate derivative with broad-spectrum anti-DNA virus activity for the treatment of CIN III.
  • Cidofovir 1% in gel was applied three times, every other day, on the cervix of each of 15 women with biopsy proven CIN III.
  • Within 1 month after the start of treatment, the cervix was removed surgically.
  • In 7 of the 15 patients the histology showed a complete response, whereas 5 patients had a partial response characterized by the persistence of CIN II-III lesions, 1 patient had a dysplasia of lower grade (CIN I), and 2 patients did not show differences in the histology.
  • Cidofovir 1% gel was able to inhibit partially or completely cervical dysplasia lesions after only three applications (every other day).
  • This effect was specific and tissue other than the dysplastic epithelium was not affected by the treatment.
  • [MeSH-major] Antiviral Agents / therapeutic use. Cervical Intraepithelial Neoplasia / drug therapy. Cytosine / analogs & derivatives. Organophosphonates. Organophosphorus Compounds / therapeutic use. Papillomavirus Infections / drug therapy. Tumor Virus Infections / drug therapy. Uterine Cervical Neoplasms / drug therapy
  • [MeSH-minor] Adult. Biopsy. Cervix Uteri / pathology. Cervix Uteri / surgery. Cervix Uteri / virology. Conization. Female. Humans. Immunohistochemistry. Middle Aged. Papillomaviridae / drug effects. Papillomaviridae / isolation & purification. Polymerase Chain Reaction

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • COS Scholar Universe. author profiles.
  • International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2000 Wiley-Liss, Inc.
  • (PMID = 10596022.001).
  • [ISSN] 0146-6615
  • [Journal-full-title] Journal of medical virology
  • [ISO-abbreviation] J. Med. Virol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] UNITED STATES
  • [Chemical-registry-number] 0 / Antiviral Agents; 0 / Organophosphonates; 0 / Organophosphorus Compounds; 8J337D1HZY / Cytosine; JIL713Q00N / cidofovir
  •  go-up   go-down


26. Del Priore G, Gudipudi DK, Montemarano N, Restivo AM, Malanowska-Stega J, Arslan AA: Oral diindolylmethane (DIM): pilot evaluation of a nonsurgical treatment for cervical dysplasia. Gynecol Oncol; 2010 Mar;116(3):464-7
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Oral diindolylmethane (DIM): pilot evaluation of a nonsurgical treatment for cervical dysplasia.
  • OBJECTIVE: Standard surgical treatment for CIN may impair fertility generating a need for alternative treatment options.
  • We tested the efficacy and toxicity of oral DIM in the treatment of CIN 2 or 3 lesions.
  • METHODS: Patients with biopsy-proven cervical intraepithelial neoplasia (CIN) 2 or 3 scheduled for loop electrosurgical excision procedure (LEEP) were randomized 2:1 to receive diindolylmethane (DIM) (BioResponse-DIM, BioResponse, Boulder, CO) orally at approximately 2 mg/kg/day for 12 weeks or placebo (defatted rice bran, BioResponse).
  • At enrollment, 58% were diagnosed with CIN 2 and 42% with CIN 3, 57% of subjects were Caucasian, 15% African American, 12% Hispanic and 17% Asian.
  • During treatment 2 subjects (3%) complained of nausea (grade 2) at the 3- to 4-month visit.
  • Twenty-one subjects (47%) in the DIM group had improved CIN with a decrease by 1-2 grades or a normal result.
  • Median time to improvement was 5 months.
  • Stratifying by level of dysplasia, age, race, HPV status, tobacco use, contraceptive used did not alter the results.
  • We observed a high rate of clinically significant improvement in confirmed CIN 2 or 3 lesions among both treatment groups in this randomized clinical trial.
  • [MeSH-major] Cervical Intraepithelial Neoplasia / drug therapy. Indoles / administration & dosage. Uterine Cervical Neoplasms / drug therapy


27. Buxant F, Bucella D, Anaf V, Simon P, Noël JC: Glucocorticoid receptor expression in cervical intraepithelial neoplasia and invasive squamous cell carcinoma of the cervix. Eur J Gynaecol Oncol; 2009;30(3):259-62
MedlinePlus Health Information. consumer health - Cervical Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Glucocorticoid receptor expression in cervical intraepithelial neoplasia and invasive squamous cell carcinoma of the cervix.
  • OBJECTIVES: Glucocorticoids (GCs) are used in cancer treatment to cause programmed cell death in transformed cells of the hematopoietic system and to lessen side-effects as nausea, vomiting, edema formation and allergies to specific chemotherapeutic agents.
  • GCs act also as cofactor with human papillomaviruses in the etiology of cervical cancer.
  • Moreover, recently GCs were described as inhibitors of some chemotherapy or radiation-induced apoptosis.
  • METHODS: To clarify the issue, we tested by immunohistochemistry the expression status of GR in normal cervix epithelium (n = 30), in low-grade cervical intraepithelial neoplasia (LSIL) (n = 30), in high-grade cervical intraepithelial neoplasia (HSIL) (n = 30) and in invasive squamous cell carcinoma (ISCC) (n = 30).
  • CONCLUSION: Because GCs could play a positive role in the progression of cancer, our demonstration of GR persistence in cervix cancer cells raises concern about the widespread combined use of GCs with antineoplastic drugs or agents in the clinical management of cervix cancer in women.
  • [MeSH-major] Carcinoma, Squamous Cell / metabolism. Cervical Intraepithelial Neoplasia / metabolism. Receptors, Glucocorticoid / metabolism. Uterine Cervical Neoplasms / metabolism

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • Genetic Alliance. consumer health - Cervical Intraepithelial Neoplasia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19697616.001).
  • [ISSN] 0392-2936
  • [Journal-full-title] European journal of gynaecological oncology
  • [ISO-abbreviation] Eur. J. Gynaecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Receptors, Glucocorticoid
  •  go-up   go-down


28. Sikorski M, Bobek M, Zrubek H, Marcinkiewicz J: Dynamics of selected MHC class I and II molecule expression in the course of HPV positive CIN treatment with the use of human recombinant IFN-gamma. Acta Obstet Gynecol Scand; 2004 Mar;83(3):299-307
International Agency for Research on Cancer - Screening Group. diagnostics - A practical manual on visual screening for cervical neoplasia .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dynamics of selected MHC class I and II molecule expression in the course of HPV positive CIN treatment with the use of human recombinant IFN-gamma.
  • BACKGROUND: Studies consistently reveal downregulation of major histocompatibility complex (MHC)-I molecules or/and selective loss of individual MHC-I alleles and upregulation of MHC-II molecules in the areas of cervical intraepithelial neoplasia (CIN) and in cervical cancers.
  • In vitro studies demonstrated the interferon-gamma (IFN-gamma) potential of MHC class I and II molecule upregulation followed by increased cytolytic response against some cervical cancer cell lines.
  • AIM OF THE STUDY: In vivo assessment of the correlation between regression/persistence state of CIN and the IFN-gamma-induced changes in both class of selected MHC molecule expression.
  • METHODS: Seventeen subjects with CIN I/CIN II associated with high-risk HPV infection underwent uniform IFN-gamma treatment (four intracervical injections over 2-day interval for a total dose of 6,000,000 IU).
  • Immunohistochemical staining has been performed within cervical punch biopsy specimens with the use of monoclonal antibody reacting with HLA-DR, HLA-HC and HLA-Bw4, and the mean proportion of given molecules expressing keratinocytes was counted before, immediately after and 2 months after IFN-gamma treatment RESULTS: The analysis revealed a rapid and significant increase of the HLA-Bw4 proportion in response to IFN-gamma, persistent in the group of complete responders (with CIN clearance).
  • No significant changes in the proportion of HLA-HC 10 positive cells in response to IFN-gamma administration was demonstrated, nor a significant increase in HLA-DR positivity; however, the transient trend towards increasing the proportion of HLA-DR immediately after treatment completion was observed.
  • CONCLUSIONS: Upregulation of selected MHC class I allele expression, but not necessary MHC class II or heavy chain fragments of MHC-I, induced by IFN-gamma correlates with the resolution of cervical intraepithelial lesions and high-risk HPV DNA clearance in vivo.
  • [MeSH-major] Cervical Intraepithelial Neoplasia / drug therapy. Histocompatibility Antigens Class I / analysis. Histocompatibility Antigens Class II / analysis. Interferon-gamma / administration & dosage. Papillomavirus Infections / diagnosis. Uterine Cervical Neoplasms / drug therapy
  • [MeSH-minor] Adult. Biomarkers, Tumor / blood. Biopsy, Needle. DNA, Viral / analysis. Dose-Response Relationship, Drug. Drug Administration Schedule. Female. Follow-Up Studies. Humans. Immunohistochemistry. Injections, Intralesional. Middle Aged. Neoplasm Staging. Papillomaviridae / isolation & purification. Probability. Prospective Studies. Recombinant Proteins. Statistics, Nonparametric. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14995928.001).
  • [ISSN] 0001-6349
  • [Journal-full-title] Acta obstetricia et gynecologica Scandinavica
  • [ISO-abbreviation] Acta Obstet Gynecol Scand
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / DNA, Viral; 0 / Histocompatibility Antigens Class I; 0 / Histocompatibility Antigens Class II; 0 / Recombinant Proteins; 82115-62-6 / Interferon-gamma
  •  go-up   go-down


29. Hefler L, Grimm C, Tempfer C, Reinthaller A: Treatment with vaginal progesterone in women with low-grade cervical dysplasia: a phase II trial. Anticancer Res; 2010 Apr;30(4):1257-61
Hazardous Substances Data Bank. PROGESTERONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment with vaginal progesterone in women with low-grade cervical dysplasia: a phase II trial.
  • BACKGROUND: The development of low-grade cervical dysplasia (CIN I) has been linked to a decrease of apoptosis and Langerhans cell (LC) count in the cervical epithelium and to an increase in the expression of various adhesion molecules.
  • We hypothesized that vaginal progesterone would increase the regression rate in women with CIN I.
  • MATERIALS AND METHODS: A non-randomized, open phase II trial with vaginal progesterone as treatment of CIN I was performed.
  • The control group consisted of 96 consecutive women with CIN I treated prior and after the study period.
  • RESULTS: The mean (standard deviation) age of women in the treatment and control groups was 32.0 (7.6) and 32.6 (8.5) years, respectively.
  • A total of 30% and 38.3% of CIN I regressed in the treatment and control group, respectively.
  • In a multivariate model, a higher number of children, a higher lifetime number of sexual partners, a lower age at first intercourse, non-use of condoms as contraception, current smoking, and treatment with vaginal progesterone were associated with a higher probability of having persistent or progressive CIN.
  • Current smoking and treatment with vaginal progesterone were associated with a higher probability of undergoing LLETZ.
  • CONCLUSION: Treatment with vaginal progesterone is associated with a lower rate of disease regression and a higher rate of surgical interventions in women with CIN I.
  • We suggest that vaginal progesterone treatment should not be applied in women with known dysplasia.
  • [MeSH-major] Cervical Intraepithelial Neoplasia / drug therapy. Progesterone / administration & dosage. Progestins / administration & dosage. Uterine Cervical Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20530437.001).
  • [ISSN] 1791-7530
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Controlled Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Progestins; 0 / Suppositories; 4G7DS2Q64Y / Progesterone
  •  go-up   go-down


30. Sikorski M, Zrubek H: Recombinant human interferon gamma in the treatment of cervical intraepithelial neoplasia (CIN) associated with human papillomavirus (HPV) infection. Eur J Gynaecol Oncol; 2003;24(2):147-50
MedlinePlus Health Information. consumer health - Cervical Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Recombinant human interferon gamma in the treatment of cervical intraepithelial neoplasia (CIN) associated with human papillomavirus (HPV) infection.
  • Human papillomavirus (HPV) proteins E6 & E7 are considered to be the constitutively expressed neoantigens in a vast majority of cervical squamous intraepithelial lesions and cancers.
  • In order to study this effect in vivo we undertook a trial in which 20 women with a definite diagnosis of cervical intraepithelial neoplasia (CIN) grade I or II with coexistent high-risk HPV infection (detected by the Hybrid Capture System) underwent four months observation followed by intracervical administration of INFgamma in cases without spontaneous regression (17 cases).
  • Human recombinant interferon gamma 1-b (Imukin) was administered intracervically four times in equal doses in two-day intervals to a total dose of 6,000,000 IU.
  • The results of therapy were verified by punch biopsy evaluation and HPV-DNA testing two months after completion, and revealed a complete response in nine women (complete regression of CIN and remission of HPV infection in 53% of treated cases) and partial response in four cases (lower grade of CIN or/and remission of HPV infection--23.5%).
  • The differences between spontaneous (before treatment) and treatment-related regressions were significant at p < 0.05.
  • We conclude that in selected cases (mainly young women who have not completed their procreation and are compliant with the therapy) a conservative approach to CIN management with intracervical IFNgamma injections seems to be a valuable method.
  • [MeSH-major] Antiviral Agents / therapeutic use. Cervical Intraepithelial Neoplasia / drug therapy. Interferon-gamma / therapeutic use. Papillomaviridae. Papillomavirus Infections / drug therapy. Uterine Cervical Neoplasms / drug therapy
  • [MeSH-minor] Adult. Female. Humans. Middle Aged. Prospective Studies. Recombinant Proteins. Treatment Outcome. Vaginal Smears

  • Genetic Alliance. consumer health - Cervical Intraepithelial Neoplasia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12701965.001).
  • [ISSN] 0392-2936
  • [Journal-full-title] European journal of gynaecological oncology
  • [ISO-abbreviation] Eur. J. Gynaecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Antiviral Agents; 0 / Recombinant Proteins; 82115-62-6 / Interferon-gamma
  •  go-up   go-down


31. Zou C, Vlastos AT, Yang L, Wang J, Nishioka K, Follen M: Effects of difluoromethylornithine on growth inhibition and apoptosis in human cervical epithelial and cancerous cell lines. Gynecol Oncol; 2002 May;85(2):266-73
Hazardous Substances Data Bank. Eflornithine .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effects of difluoromethylornithine on growth inhibition and apoptosis in human cervical epithelial and cancerous cell lines.
  • OBJECTIVE: Difluoromethylornithine(DFMO), an irreversible inhibitor of ornithine decarboxylase and an angiogenesis inhibitor, has been used in phase I cervical intraepithelial neoplasia (CIN) trials, producing a 50% regression of CIN 3 lesions.
  • METHODS: Four immortalized cervical epithelial cell lines, serving as in vitro models of precancerous CIN lesions, and nine cervical carcinoma cell lines were studied.
  • DFMO's growth inhibitory effect was tested in monolayer culture and in semisolid medium, and concentrations required for a 50% growth inhibition (IC(50)) with a 5-day treatment were determined.
  • RESULTS: DFMO inhibited growth of immortalized cervical epithelial cell lines and cervical cancer cell lines in monolayer culture and in semisolid medium.
  • The immortalized cervical epithelial cell lines were more sensitive than the cervical cancer cell lines to DFMO's growth inhibitory effect.
  • Concentrations required for 50% growth inhibition after a 5-day treatment ranged from 100 microM to >5 mM for cervical carcinoma cell lines and from 100 microM to 1 mM for immortalized cervical epithelial cell lines.
  • CONCLUSION: DFMO inhibits the growth of cervical precancerous and cancerous cells in vitro in a dose-dependent and time-dependent manner, partially through inducing apoptosis.
  • [MeSH-major] Anticarcinogenic Agents / pharmacology. Apoptosis / drug effects. Eflornithine / pharmacology. Uterine Cervical Neoplasms / prevention & control
  • [MeSH-minor] Cell Division / drug effects. Cervical Intraepithelial Neoplasia / drug therapy. Cervical Intraepithelial Neoplasia / pathology. Female. Growth Inhibitors / pharmacology. Humans. Neoplastic Stem Cells / drug effects. Neoplastic Stem Cells / pathology. Tumor Cells, Cultured


32. Russomano F, Reis A, Camargo MJ, Grinsztejn B, Tristão MA: Recurrence of cervical intraepithelial neoplasia grades 2 or 3 in HIV-infected women treated by large loop excision of the transformation zone (LLETZ). Sao Paulo Med J; 2008 Jan 2;126(1):17-22
International Agency for Research on Cancer - Screening Group. diagnostics - Planning and Implementing Cervical Cancer Prevention and Control Programs: A Manual for Managers .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Recurrence of cervical intraepithelial neoplasia grades 2 or 3 in HIV-infected women treated by large loop excision of the transformation zone (LLETZ).
  • CONTEXT AND OBJECTIVE: Women infected by HIV are more likely to have cervical cancer and its precursors.
  • Treatment of the precursor lesions can prevent this neoplasia.
  • The aim of this study was to assess the likelihood of recurrent cervical intraepithelial neoplasia grades 2 or 3 (CIN 2-3) in HIV-infected women, compared with HIV-negative women, all treated by large loop excision of the transformation zone (LLETZ).
  • METHOD: 55 HIV-positive and 212 HIV-negative women were followed up after LLETZ for CIN 2-3 (range: 6-133 months).
  • RESULTS: The incidence of recurrent CIN 2-3 was 30.06/10,000 woman-months in the HIV-positive group and 4.88/10,000 woman-months in the HIV-negative group (relative risk, RR = 6.16; 95% confidence interval, CI: 2.07-18.34).
  • We were unable to demonstrate other prognostic factors relating to CIN recurrence, but the use of highly active antiretroviral therapy (HAART) may decrease the risk of this occurrence among HIV patients.
  • CONCLUSION: After LLETZ there is a higher risk of recurrence of CIN 2-3 among HIV-positive women than among HIV-negative women.
  • This higher risk was not influenced by margin status or grade of cervical disease treated.
  • [MeSH-major] Cervical Intraepithelial Neoplasia / surgery. HIV Infections / complications. Neoplasm Recurrence, Local / prevention & control. Uterine Cervical Neoplasms / surgery
  • [MeSH-minor] Adolescent. Adult. Antiretroviral Therapy, Highly Active. Brazil / epidemiology. CD4 Lymphocyte Count. Cohort Studies. Colposcopy / methods. Female. Follow-Up Studies. HIV Seropositivity / complications. HIV Seropositivity / drug therapy. HIV Seropositivity / virology. Humans. Middle Aged. Recurrence. Risk Factors. Time Factors. Young Adult


33. Piura B, Rabinovich A, Huleihel M: [Matrix metalloproteinases and their tissue inhibitors in malignancies of the female genital tract]. Harefuah; 2003 Nov;142(11):786-91, 804

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Matrix metalloproteinases and their tissue inhibitors in malignancies of the female genital tract].
  • Their proteolytic activity depends on their binding to metal Zinc and is controlled by tissue inhibitors of MMP (TIMPs).
  • Since MMPs may serve as markers of tumor behavior and as predictors of survival and since synthetic inhibitors of MMP may have a place in the treatment of cancer, researching MMPs and their tissue inhibitors in malignant diseases has attracted growing attention.
  • Studies on MMPs and their tissue inhibitors in malignancies of the female genital tract have shown the following:.
  • 1) In ovarian carcinoma and cervical carcinoma, over-expression of MMP-2 and MMP-9 is associated with invasiveness, metastatic spread and poor prognosis;.
  • 3) In cervical intra-epithelial neoplasia (CIN), measuring MMP-2 can assist in identifying high-risk for progression CIN I and CIN II; 4).
  • It is speculated that using synthetic drugs that inhibit MMPs in combination with conventional chemotherapy may contribute to the improvement of treatment results in cancer patients.
  • [MeSH-major] Genital Neoplasms, Female / enzymology. Genital Neoplasms, Female / pathology. Matrix Metalloproteinases / metabolism. Tissue Inhibitor of Metalloproteinases / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14631913.001).
  • [ISSN] 0017-7768
  • [Journal-full-title] Harefuah
  • [ISO-abbreviation] Harefuah
  • [Language] heb
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Israel
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Tissue Inhibitor of Metalloproteinases; EC 3.4.24.- / Matrix Metalloproteinases
  • [Number-of-references] 32
  •  go-up   go-down


34. Snoeck R, Andrei G, De Clercq E: Cidofovir in the treatment of HPV-associated lesions. Verh K Acad Geneeskd Belg; 2001;63(2):93-120, discussion 120-2
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cidofovir in the treatment of HPV-associated lesions.
  • The acyclic nucleoside phosphonate cidofovir (CDV) has proved efficacious in the treatment of different clinical manifestations of HPV-induced epithelial cell proliferation.
  • Local intratumor injections of CDV in an immunocompetent patient with hypopharyngeal/esophageal papillomatous lesions, PCR-positive for HPV types 16 and 18, resulted in a complete regression of the tumor.
  • In addition, CDV topical gel has been successfully used for the treatment of severe, relapsing anogenital HPV lesions and cervical intraepithelial neoplasia (CIN) grade III.
  • In vitro, treatment of HPV-positive cells (compared to normal primary human keratinocytes) with CDV has resulted in a concentration- and time-dependent inhibition of cell proliferation.
  • Different parameters of apoptosis, i.e., (i) induction of CPP32 (caspase-3) protease activity, (ii) translocation of phosphatidylserine (PS) from the inner part of the plasma membrane to the outer layer, (iii) disintegration of the nuclear matrix protein (NMP), (iv) DNA fragmentation, (v) number of cells in apoptotic phase following cell cycle analysis, showed that the mechanism of cell death following treatment with CDV is based on apoptosis.
  • In conclusion, CDV has great potential in the treatment of severe HPV-induced proliferative lesions, either laryngeal, esophageal/pharyngeal or genital.
  • As CDV has proved able to induce apoptosis, in a time- and concentration-dependent manner, in a number of HPV-positive cell lines, the regression of papillomatous tumors observed with CDV in patients, may be due, at least in part, to the induction of apoptosis.
  • [MeSH-major] Antiviral Agents / therapeutic use. Cytosine / therapeutic use. Organophosphonates. Organophosphorus Compounds / therapeutic use. Papillomaviridae. Papillomavirus Infections / drug therapy. Tumor Virus Infections / drug therapy
  • [MeSH-minor] Administration, Topical. Apoptosis / drug effects. Cell Division / drug effects. Female. Humans. Injections, Intravenous. Male

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CIDOFOVIR .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11436421.001).
  • [ISSN] 0302-6469
  • [Journal-full-title] Verhandelingen - Koninklijke Academie voor Geneeskunde van België
  • [ISO-abbreviation] Verh. K. Acad. Geneeskd. Belg.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Belgium
  • [Chemical-registry-number] 0 / Antiviral Agents; 0 / Organophosphonates; 0 / Organophosphorus Compounds; 8J337D1HZY / Cytosine; JIL713Q00N / cidofovir
  • [Number-of-references] 57
  •  go-up   go-down


35. TOMBOLA Group: Biopsy and selective recall compared with immediate large loop excision in management of women with low grade abnormal cervical cytology referred for colposcopy: multicentre randomised controlled trial. BMJ; 2009 Jul 28;339:b2548
International Agency for Research on Cancer - Screening Group. diagnostics - Colposcopy and Treatment of Cervical Intraepithelial Neoplasia: A Beginner's Manual .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Biopsy and selective recall compared with immediate large loop excision in management of women with low grade abnormal cervical cytology referred for colposcopy: multicentre randomised controlled trial.
  • OBJECTIVES: To compare the effectiveness of punch biopsy and selective recall for treatment versus a policy of immediate treatment by large loop excision in the management of women with low grade abnormal cervical cytology referred for colposcopy.
  • DESIGN: Multicentre individually randomised controlled trial, nested within the NHS cervical screening programmes.
  • PARTICIPANTS: 1983 women, aged 20-59, with cytology showing borderline nuclear abnormalities or mild dyskaryosis, October 1999-October 2002.
  • INTERVENTIONS: Immediate large loop excision or up to four targeted punch biopsies taken immediately with recall for treatment (by large loop excision) if these showed cervical intraepithelial neoplasia grade II or III or worse.
  • MAIN OUTCOME MEASURES: Clinical end points: cumulative incidence of cervical intraepithelial neoplasia grade II or worse and grade III or worse at three years.
  • RESULTS: 879 women (44%) had a normal transformation zone at colposcopy and had no further procedures at that time.
  • Of women randomised to biopsy and recall, 157 (16%) required a second clinic visit for treatment.
  • Specimens from almost 60% (n=296) of women who underwent immediate large loop excision showed no cervical intraepithelial neoplasia (31%; n=156) or showed cervical intraepithelial neoplasia grade I (28%; n=140).
  • The percentages of women diagnosed with grade II or worse up to and including the exit examination were 22% (n=216) in the biopsy and recall arm and 23% (n=228) in the immediate large loop excision arm.
  • There was no significant difference between the arms in cumulative incidence of cervical intraepithelial neoplasia grade II or worse (adjusted relative for risk large loop excision v biopsy 1.04, 95% confidence interval 0.86 to 1.25) or grade III or worse (1.03, 0.79 to 1.34).
  • A greater proportion of disease was detected at initial investigation and less during follow-up and at exit in the immediate large loop excision arm, but time of detection did not differ significantly between arms.
  • CONCLUSION: A policy of targeted punch biopsies with subsequent treatment for cervical intraepithelial neoplasia grade II or III and cytological surveillance for grade I or less provides the best balance between benefits and harms for the management of women with low grade abnormal cytology referred for colposcopy.

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Cancer. 2003 Jul 10;105(5):687-91 [12740919.001]
  • [Cites] BJOG. 2009 Oct;116(11):1506-14 [19583712.001]
  • [Cites] J Natl Cancer Inst Monogr. 2003;(31):20-8 [12807941.001]
  • [Cites] Am J Obstet Gynecol. 2003 Jun;188(6):1406-12 [12824970.001]
  • [Cites] Br J Cancer. 2004 Mar 8;90(5):975-8 [14997192.001]
  • [Cites] Cytopathology. 2004 Oct;15(5):263-70 [15456414.001]
  • [Cites] Acta Psychiatr Scand. 1983 Jun;67(6):361-70 [6880820.001]
  • [Cites] Lancet. 1986 Sep 20;2(8508):672-3 [2876144.001]
  • [Cites] Br J Obstet Gynaecol. 1991 Jun;98(6):588-91 [1651758.001]
  • [Cites] Br J Obstet Gynaecol. 1991 Dec;98(12):1273-6 [1777461.001]
  • [Cites] Obstet Gynecol. 1992 Dec;80(6):1020-2 [1448246.001]
  • [Cites] Br J Obstet Gynaecol. 1992 Dec;99(12):1023-4 [1341890.001]
  • [Cites] Int J Gynecol Pathol. 1993 Apr;12(2):186-92 [8463044.001]
  • [Cites] BMJ. 1994 May 28;308(6941):1399-403 [8019248.001]
  • [Cites] Br J Obstet Gynaecol. 1995 Jul;102(7):545-8 [7647056.001]
  • [Cites] Br J Obstet Gynaecol. 1995 Jul;102(7):549-52 [7647057.001]
  • [Cites] Gynecol Oncol. 1996 Mar;60(3):400-3 [8774646.001]
  • [Cites] Br J Obstet Gynaecol. 1997 Dec;104(12):1380-4 [9422016.001]
  • [Cites] Obstet Gynecol. 1999 Sep;94(3):377-85 [10472863.001]
  • [Cites] Lancet Oncol. 2005 Jan;6(1):43-50 [15629275.001]
  • [Cites] J Low Genit Tract Dis. 2005 Jan;9(1):29-35 [15870519.001]
  • [Cites] J Low Genit Tract Dis. 2005 Jan;9(1):36-9 [15870520.001]
  • [Cites] Am J Obstet Gynecol. 2005 Oct;193(4):1331-7 [16202722.001]
  • [Cites] J Low Genit Tract Dis. 2006 Jan;10(1):26-38 [16378029.001]
  • [Cites] Int J Gynecol Cancer. 2006 Jan-Feb;16(1):253-6 [16445640.001]
  • [Cites] Lancet. 2006 Feb 11;367(9509):489-98 [16473126.001]
  • [Cites] Int J Gynecol Cancer. 2006 Mar-Apr;16(2):615-9 [16681735.001]
  • [Cites] Obstet Gynecol. 2006 Aug;108(2):264-72 [16880294.001]
  • [Cites] Am J Obstet Gynecol. 2006 Aug;195(2):349-53 [16677597.001]
  • [Cites] Contemp Clin Trials. 2006 Oct;27(5):449-71 [16765101.001]
  • [Cites] BJOG. 2006 Nov;113(11):1321-8 [17059394.001]
  • [Cites] BJOG. 2007 Jan;114(1):3-4 [17233854.001]
  • [Cites] BJOG. 2007 Jan;114(1):39-45 [17233858.001]
  • [Cites] Eur J Obstet Gynecol Reprod Biol. 2007 Mar;131(1):73-5 [16516371.001]
  • [Cites] Int J Technol Assess Health Care. 2007 Spring;23(2):232-9 [17493309.001]
  • [Cites] BJOG. 2007 Jun;114(6):777-8 [17516979.001]
  • [Cites] BMJ. 2009;339:b2546 [19638646.001]
  • [Cites] BMJ. 2009;339:b2549 [19638648.001]
  • [CommentIn] BMJ. 2009;339:b3014 [19638653.001]
  • (PMID = 19638647.001).
  • [ISSN] 1756-1833
  • [Journal-full-title] BMJ (Clinical research ed.)
  • [ISO-abbreviation] BMJ
  • [Language] ENG
  • [Databank-accession-numbers] ISRCTN/ ISRCTN34841617
  • [Grant] United Kingdom / Medical Research Council / / G9700808
  • [Publication-type] Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2718084
  • [Investigator] Cruickshank M; Murray G; Parkin D; Smart L; Walker E; Waugh N; Avis M; Chilvers C; Fielding K; Hammond R; Jenkins D; Johnson J; Neal K; Russell I; Seth R; Whynes D; Duncan I; Robertson A; Little J; Sharp L; Russell I; Walker L; Anthony B; Bell S; Bowie A; Brown K; Brown J; Chew K; Cochran C; Cotton S; Dean J; Dunn K; Edwards J; Evans D; Fenty J; Finlayson A; Gallagher M; Gray N; Heddle M; Innes A; Jobson D; Keillor M; MacGregor J; Mackenzie S; Mackie A; McPherson G; Okorocha I; Reilly M; Rodgers J; Thornton A; Yeats R; Alexander L; Buchanan L; Henderson S; Iterbeke T; Lucas S; Manderson G; Nicol S; Reid G; Robinson C; Sandilands T; Adrian M; Al-Sahab A; Bentley E; Brook H; Bushby C; Cannon R; Cooper B; Dowell R; Dunderdale M; Gabrawi; Guo L; Heideman L; Jones S; Lawson S; Philips Z; Platt C; Prabhakaran S; Rippin J; Thompson R; Williams E; Woolley C; Boroujerdi M; Cotton S; Harrild K; Norrie J; Day N; Marteau T; Parmar M; Patnick J; Woodman C; Altman D; Moss S; Wells M; Sharp L; Cruickshank M; Little J; Cotton S; Harrild K; Cochran C; Duncan I; Gray N; Hammond R; Smart L; Thornton A; Waugh N; Woolley C
  •  go-up   go-down


36. Khanna N, Dalby R, Tan M, Arnold S, Stern J, Frazer N: Phase I/II clinical safety studies of terameprocol vaginal ointment. Gynecol Oncol; 2007 Dec;107(3):554-62
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • This trial was designed to define the maximum tolerated dose (MTD), dose-limiting toxicity and determine the pharmacokinetic profiles of intravaginal terameprocol in women with HPV-linked cervical squamous intraepithelial neoplasia.
  • METHODS: An open label, dose escalation Phase I/II clinical trial enrolled women with biopsy confirmed CIN 1, 2 or 3.
  • Terameprocol (45 or 90 mg) was physician-administered directly to the cervix uteri in 3 once weekly applications.
  • Patients underwent colposcopic examinations, HPV testing, biomarker assessments, cytology and cervical punch biopsy.
  • There were no serious adverse events (SAEs) and possible treatment-related Adverse Events (AEs) reported were mild and self-limiting.
  • CONCLUSIONS: Terameprocol in 1% and 2% vaginal ointment use in Phase I/II trials with women with HPV-linked cervical intraepithelial neoplasia has an excellent safety profile, no SAEs reported and mild, self-limiting treatment-related AEs.
  • These data support the continued evaluation of terameprocol in in vitro and animal efficacy models followed by definitive human Phase II clinical trials in CIN.
  • [MeSH-major] Cervical Intraepithelial Neoplasia / drug therapy. Masoprocol / analogs & derivatives. Uterine Cervical Neoplasms / drug therapy
  • [MeSH-minor] Adolescent. Adult. Biomarkers, Tumor / biosynthesis. CDC2-CDC28 Kinases / biosynthesis. Dose-Response Relationship, Drug. Female. Humans. Immunohistochemistry. Inhibitor of Apoptosis Proteins. Microtubule-Associated Proteins / biosynthesis. Neoplasm Proteins / biosynthesis. Neoplasm Staging. Ointments. Papillomaviridae / classification. Papillomavirus Infections / complications. Papillomavirus Infections / virology

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • COS Scholar Universe. author profiles.
  • International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17905420.001).
  • [ISSN] 1095-6859
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / BIRC5 protein, human; 0 / Biomarkers, Tumor; 0 / Inhibitor of Apoptosis Proteins; 0 / Microtubule-Associated Proteins; 0 / Neoplasm Proteins; 0 / Ointments; 53YET703F2 / terameprocol; 7BO8G1BYQU / Masoprocol; EC 2.7.11.22 / CDC2-CDC28 Kinases
  •  go-up   go-down


37. van der Burg SH, Kwappenberg KM, O'Neill T, Brandt RM, Melief CJ, Hickling JK, Offringa R: Pre-clinical safety and efficacy of TA-CIN, a recombinant HPV16 L2E6E7 fusion protein vaccine, in homologous and heterologous prime-boost regimens. Vaccine; 2001 Jun 14;19(27):3652-60
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pre-clinical safety and efficacy of TA-CIN, a recombinant HPV16 L2E6E7 fusion protein vaccine, in homologous and heterologous prime-boost regimens.
  • Human papillomavirus (HPV) E6 and E7 oncoproteins are attractive targets for T-cell-based immunotherapy of cervical intraepithelial neoplasia (CIN) and cancer.
  • A newly designed vaccine, comprising the HPV16 L2, E6 and E7 as a single fusion protein (TA-CIN), was shown to elicit HPV16-specific CTL, T-helper cells and antibodies in a pre-clinical mouse model.
  • CTL immunity was optimally induced when TA-CIN was employed in heterologous prime-boost regimens in combination with TA-HPV, a clinical grade vaccinia-based vaccine.
  • These data provide a scientific basis for the use of TA-CIN, alone or in combination with TA-HPV in future human trials.
  • [MeSH-major] Cancer Vaccines / toxicity. Capsid / toxicity. Capsid Proteins. Oncogene Proteins, Viral / toxicity. Papillomaviridae / immunology. Recombinant Fusion Proteins / toxicity
  • [MeSH-minor] Animals. Antigens, Neoplasm / administration & dosage. Antigens, Neoplasm / immunology. Antigens, Neoplasm / therapeutic use. Antigens, Neoplasm / toxicity. Antigens, Viral / administration & dosage. Antigens, Viral / immunology. Antigens, Viral / therapeutic use. Antigens, Viral / toxicity. Cell Line. Cell Line, Transformed. Cervical Intraepithelial Neoplasia / prevention & control. Cervical Intraepithelial Neoplasia / therapy. Cervical Intraepithelial Neoplasia / virology. Drug Evaluation, Preclinical. Immunotherapy. Mice. Mice, Inbred C57BL. Papillomavirus E7 Proteins. Vaccines, Acellular / administration & dosage. Vaccines, Acellular / immunology. Vaccines, Acellular / therapeutic use. Vaccines, Acellular / toxicity

  • SciCrunch. DrugBank: Data: Chemical .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11395199.001).
  • [ISSN] 0264-410X
  • [Journal-full-title] Vaccine
  • [ISO-abbreviation] Vaccine
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Antigens, Viral; 0 / Cancer Vaccines; 0 / Capsid Proteins; 0 / L2 protein, Human papillomavirus type 16; 0 / Oncogene Proteins, Viral; 0 / Papillomavirus E7 Proteins; 0 / Recombinant Fusion Proteins; 0 / Vaccines, Acellular; 0 / oncogene protein E7, Human papillomavirus type 16
  •  go-up   go-down






Advertisement